Company Snapshot
Flare Therapeutics is a Biotech company, based in Cambridge, Massachusetts, USA, founded 2021.
Recent changes
- Jun 30, 2026Jun 30, 2026Raised $85M Series C GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Third Rock Ventures GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Nextech Invest GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Casdin Capital GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Invus GlobeNewswire
Earlier changes (5)
- Jun 30, 2026Jun 30, 2026New investor: Boxer Capital GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Pfizer Ventures GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Eli Lilly GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: GordonMD Global Investments GlobeNewswire
- Jun 30, 2026Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEO Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Series C | $85M | — | Pulse story |
Investors
Latest Pulse
- Jul 5, 2026Biotech VCs Are Betting Big on Single Clinical TrialsCelea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.→
- Jul 2, 2026Crunchbase: The Week's 10 Biggest Funding Rounds, Led by Joulent's $1.75B Energy RaiseCrunchbase News' roundup of the week's 10 biggest funding rounds (June 27-July 2) was led by Houston-based energy infrastructure provider Joulent's $1.75 billion raise from National Grid Ventures, aimed squarely at AI and compute-intensive industries' power needs. Together AI's $800M Series C and Venice AI's $65M unicorn round both placed inside the top 10, alongside biotech, legal-tech, sports and video-AI rounds spanning a genuinely broad set of categories beyond pure frontier-model AI.→
- Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEOFlare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.→
- Jun 8, 2026HCW Biologics Files S-1 for Small $5.6M Best-Efforts RaiseHCW Biologics filed an S-1 for a best-efforts offering of up to $5.6 million, a modest raise reflecting the tighter capital-access conditions many small-cap clinical-stage biotechs still face despite the broader 2026 IPO boom.→
Coverage Timeline
newest firstAll Coverage
FUNDING$391M+ combined across 3 single-trial bets
Biotech VCs Are Betting Big on Single Clinical Trials
Celea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.
Flare Therapeutics Raises $85M, Names New CEO
FUNDING$85M Series C
Flare Therapeutics Raises $85M, Names New CEO
Flare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.
Related Companies
Flare Therapeutics FAQ
Who are Flare Therapeutics's investors?
Flare Therapeutics's investors include Nextech Invest, Third Rock Ventures, Agent Capital, Boxer Capital, Casdin Capital, and 7 more (As of 2026-07-31T14:35:19Z).
Sources & methodologyshow
Where these figures come from
- GlobeNewswireprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.